[go: up one dir, main page]

DK3038654T3 - Ny anvendelse - Google Patents

Ny anvendelse Download PDF

Info

Publication number
DK3038654T3
DK3038654T3 DK14761702.1T DK14761702T DK3038654T3 DK 3038654 T3 DK3038654 T3 DK 3038654T3 DK 14761702 T DK14761702 T DK 14761702T DK 3038654 T3 DK3038654 T3 DK 3038654T3
Authority
DK
Denmark
Prior art keywords
new use
new
Prior art date
Application number
DK14761702.1T
Other languages
English (en)
Inventor
Victor Chengwei Shi
Martin Lefkowitz
Adel Remond Rizkala
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51494327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3038654(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/056680 external-priority patent/WO2015030711A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3038654T3 publication Critical patent/DK3038654T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DK14761702.1T 2013-08-26 2014-08-26 Ny anvendelse DK3038654T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2013/056680 WO2015030711A1 (en) 2013-08-26 2013-08-26 New use
US201461972933P 2014-03-31 2014-03-31
PCT/IB2014/064074 WO2015028941A1 (en) 2013-08-26 2014-08-26 New use

Publications (1)

Publication Number Publication Date
DK3038654T3 true DK3038654T3 (da) 2020-02-03

Family

ID=51494327

Family Applications (3)

Application Number Title Priority Date Filing Date
DK19202854.6T DK3626270T3 (da) 2013-08-26 2014-08-26 Behandling af kardiovaskulære sygdomme
DK23202190.7T DK4321157T3 (da) 2013-08-26 2014-08-26 Ny anvendelse af en kombination af en angiotensinreceptorblokker (arb) med en neutral endopeptidasehæmmer (nepi)
DK14761702.1T DK3038654T3 (da) 2013-08-26 2014-08-26 Ny anvendelse

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK19202854.6T DK3626270T3 (da) 2013-08-26 2014-08-26 Behandling af kardiovaskulære sygdomme
DK23202190.7T DK4321157T3 (da) 2013-08-26 2014-08-26 Ny anvendelse af en kombination af en angiotensinreceptorblokker (arb) med en neutral endopeptidasehæmmer (nepi)

Country Status (16)

Country Link
US (2) US20160213646A1 (da)
EP (4) EP4321157B1 (da)
JP (1) JP6097888B2 (da)
CY (1) CY1122531T1 (da)
DK (3) DK3626270T3 (da)
ES (3) ES2767084T3 (da)
FI (2) FI4321157T3 (da)
HR (3) HRP20240034T1 (da)
HU (3) HUE047186T2 (da)
LT (3) LT3626270T (da)
PL (3) PL3038654T3 (da)
PT (3) PT4321157T (da)
RS (3) RS59816B1 (da)
SI (3) SI3038654T1 (da)
SM (1) SMT202500001T1 (da)
WO (1) WO2015028941A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2767084T3 (es) 2013-08-26 2020-06-16 Novartis Ag Nuevo uso
EP3253740A1 (en) * 2015-02-06 2017-12-13 Mylan Laboratories Ltd. Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
WO2016193883A1 (en) * 2015-05-29 2016-12-08 Novartis Ag Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
CN107510653A (zh) * 2016-06-17 2017-12-26 常州爱诺新睿医药技术有限公司 一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法
CN106491600A (zh) * 2015-09-06 2017-03-15 常州方楠医药技术有限公司 无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
CN106580908A (zh) * 2015-10-16 2017-04-26 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
JP6810152B2 (ja) 2016-02-03 2021-01-06 ノバルティス アーゲー サクビトリルおよびバルサルタンの組合せの新規使用
CN106176681A (zh) * 2016-08-25 2016-12-07 泰力特医药（湖北）有限公司 一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
US20210177803A1 (en) * 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN113286585B (zh) * 2019-09-20 2022-11-08 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
ATE243515T1 (de) * 1997-01-10 2003-07-15 Merck & Co Inc Verwendung der angiotensin ii-antagonisten losartan und exp-3174 zur behandlung von symptomatisches herzversagen
DE60315795T2 (de) * 2002-01-17 2008-06-05 Novartis Ag Pharmazeutische zusammensetzung enthaltend valsartan und nep-inhibitoren
TW200509909A (en) * 2003-05-16 2005-03-16 Novartis Ag Use of organic compounds
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
ES2939163T3 (es) 2007-11-06 2023-04-19 Novartis Ag Composiciones farmacéuticas basadas en superestructuras de antagonista/bloqueante del receptor de angiotensina (ARB) e inhibidor de la endopeptidasa neutra (NEP)
SI2752189T1 (sl) 2008-11-22 2017-02-28 F. Hoffmann-La Roche Ag Uporaba anti-vegf protitelesa v kombinaciji s kemoterapijo za zdravljenje prsnega raka
PH12013500231A1 (en) 2010-08-24 2017-08-09 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
EP3943084A1 (en) 2012-08-24 2022-01-26 Novartis AG Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
JP2016530282A (ja) * 2013-08-26 2016-09-29 ノバルティス アーゲー 新規使用
ES2767084T3 (es) 2013-08-26 2020-06-16 Novartis Ag Nuevo uso

Also Published As

Publication number Publication date
SI3038654T1 (sl) 2020-02-28
WO2015028941A1 (en) 2015-03-05
EP3038654B1 (en) 2019-10-30
RS59816B1 (sr) 2020-02-28
HRP20200060T1 (hr) 2020-04-03
RS66371B1 (sr) 2025-02-28
US20160213646A1 (en) 2016-07-28
EP3626270A1 (en) 2020-03-25
LT4321157T (lt) 2025-01-10
EP4321157B1 (en) 2024-10-23
PL4321157T3 (pl) 2025-03-03
EP4321157A3 (en) 2024-05-15
HUE047186T2 (hu) 2020-04-28
JP2016528303A (ja) 2016-09-15
PT3038654T (pt) 2020-02-04
LT3626270T (lt) 2024-01-25
LT3038654T (lt) 2020-01-27
JP6097888B2 (ja) 2017-03-15
PL3626270T3 (pl) 2024-04-08
ES2968541T3 (es) 2024-05-10
PT3626270T (pt) 2024-01-11
PL3038654T3 (pl) 2020-05-18
EP3038654A1 (en) 2016-07-06
HUE069419T2 (hu) 2025-03-28
PT4321157T (pt) 2025-01-08
EP4321157A2 (en) 2024-02-14
RS65037B1 (sr) 2024-02-29
HRP20240034T1 (hr) 2024-03-29
HUE064634T2 (hu) 2024-04-28
DK3626270T3 (da) 2024-01-15
US20210077461A1 (en) 2021-03-18
CY1122531T1 (el) 2021-01-27
SMT202500001T1 (it) 2025-03-12
DK4321157T3 (da) 2024-12-16
SI4321157T1 (sl) 2025-03-31
FI3626270T3 (fi) 2024-01-11
EP4512397A3 (en) 2025-05-14
HRP20241763T1 (hr) 2025-03-14
SI3626270T1 (sl) 2024-03-29
EP4512397A2 (en) 2025-02-26
ES2767084T3 (es) 2020-06-16
FI4321157T3 (fi) 2025-01-20
ES3001196T3 (es) 2025-03-04
EP3626270B1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
FIC20240001I1 (fi) Tislelitsumabi
NL301272I2 (nl) Fezolinetant
NL301194I2 (nl) mosunetuzumab
NL301171I1 (nl) Tigolaner
NL301247I2 (nl) mirikizumab
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
DK3038654T3 (da) Ny anvendelse
DK3052081T3 (da) Pastil
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
FR3003883B3 (fr) Plinthe
DK2946640T3 (da) Langmuir-probe
EP2943489A4 (en) DEUTERATED MOMELOTINIB
EP2969096A4 (en) Bottle pressurization delivery system
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
HUE036203T2 (hu) Spiro-oxazolonok
DE112014001252A5 (de) Aufbissschiene
PT3022200T (pt) Novos agentes antimaláricos
DK3086679T3 (da) Sportssko